This study describes blood culture collection rates, results, and microbiology laboratory charges for 4 leading pediatric inpatient diagnoses (asthma, bronchiolitis, pneumonia, and skin and soft tissue infection [SSTI]) in low-risk patients. Patients with complex chronic conditions were excluded. Data were collected via administrative billing data and chart review. Descriptive statistics were performed; χ 2 tests were used for categorical variables, and nonparametric tests were used for continuous variables because of non-normal distributions.
However, false-positive results (ie, contaminant blood cultures) can limit test utility, expand resource utilization, and increase hospital charges via repeat testing, antibiotic exposure, hospitalization, additional invasive testing and management (eg, lumbar puncture, central catheter), and specialty consultations. [3] [4] [5] For example, Segal and Chamberlain 4 described contaminant blood cultures in 85 children that added more than $78 000 in unnecessary charges. This amount does not include unmeasured costs, such as the fi nancial and emotional impact on patients and their families. There have been numerous studies to identify best practices to prevent blood culture contamination, many of which have shown signifi cant reduction in contamination rates. [6] [7] [8] [9] [10] [11] Resource overutilization can also occur when blood cultures are collected unnecessarily. To reduce unnecessary blood culture collection, the initial step is assessing risk of bacteremia to avoid blood culture collection in low-risk patients. For example, well-established clinical practice guidelines for children with asthma and bronchiolitis do not support routine blood culture collection. [12] [13] [14] Similarly, the literature demonstrates no evidence of clinically signifi cant bacteremia in patients with skin and soft tissue infection (SSTI), even in the era of methicillin-resistant Staphylococcus aureus (MRSA). 15, 16 In contrast, guidelines for inpatient community-acquired pneumonia (CAP) management do recommend considering blood culture testing for inpatients with moderate to severe bacterial pneumonia. 17, 18 However, high rates of negative culture results can represent overutilization as well, and they suggest a need to defi ne or refi ne clinical practice guidelines. Although true-positive results of blood cultures may represent pathogenic bacteremia, they may be unnecessary if they do not change empirical management, thereby representing another form of resource overutilization. In addition, it is possible that even when a truepositive result on blood culture changes management, the change made may not be evidence based and therefore may not provide a true benefi t to the patient.
Given these increased charges and burden on our health care system, reducing blood culture overutilization is an opportunity to improve value-driven care. The present study describes blood culture collection rates, results, and microbiology laboratory charges as a proxy for fi nancial impact for 4 leading pediatric inpatient diagnoses (ie, asthma, bronchiolitis, CAP, SSTI) in low-risk patients. We hypothesized that there is potential resource overutilization with regard to blood culture usage for these 4 common diagnoses among hospitalized children.
METHODS

Overview
This retrospective descriptive cohort study was conducted at an urban, academic, quaternary children's hospital from January 1, 2011, to December 31, 2011. This study qualifi ed for exempt status from the local institutional review board.
Patient Selection
We included patients 6 months to 18 years of age with a primary diagnosis of asthma (International Classifi cation of Diseases, Ninth Revision [ICD-9] codes 493.91-493.92), bronchiolitis (ICD-9 codes 466.11 and 466. 19 ), SSTI (ICD-9 codes 680.00-686.99), and bacterial or unidentifi ed pneumonia (ICD-9 codes 481.00-486.00). We excluded patients with any secondary diagnoses of complex chronic conditions to establish a cohort of patients without other comorbid conditions. 19
Data Collection
We used administrative billing data to identify all inpatient, outpatient, and emergency department (ED) setting visits for the study diagnoses during the study period. Patients with ICD-9 codes consistent with complex chronic conditions were excluded. Blood culture utilization was determined for each setting and diagnosis. Inpatients with blood culture collection were identifi ed, and chart review was completed for all inpatients with blood cultures collected.
The primary outcome was to describe blood culture utilization rates according to diagnosis and setting. Secondary outcomes were description of blood culture results and, as a proxy for fi nancial impact, gross microbiology laboratory charges. These approximate charges included blood culture collection ($300), organism identifi cation ($100), and antibiotic sensitivity ($150).
These charges represent what a facility bills payers and are different and typically much higher than "costs," which represent actual expenses incurred by the facility. Charges vary among institutions and are a function of overhead expenses and negotiated payer reimbursements. Despite this limitation of overrepresenting health care expenses, charges are easier to ascertain than cost and thus commonly used a proxy for fi nancial burden. 20 Finally, when a blood culture result was positive, we recorded whether the organism represented a true-positive VOLUME 4 • ISSUE 2 www.hospitalpediatrics.org or a false-positive result based on the treatment team's chart documentation and any apparent change in clinical management. These changes included further testing; change in antibiotic selection, duration, or route; and extended length of stay (LOS).
Analysis
Descriptive statistics were performed to determine blood culture utilization rates overall and according to diagnosis. Comparisons with categorical variables were conducted by using χ 2 tests, and nonparametric tests were used for continuous variables due to nonnormal distributions. SPSS version 21.0 (IBM SPSS Statistics, IBM Corporation, Armonk, NY) was used for analysis.
RESULTS
Blood Culture Utilization According to Diagnosis and Setting
Administrative data review identifi ed 5159 encounters from January 1, 2011, to December 31, 2011. Thirty-two percent (n = 1629) were inpatient encounters and 68% (n = 3530) were ED or outpatient encounters. Overall, blood cultures were collected in 3% (n = 111) of total ED or outpatient encounters and 21% (n = 343) of inpatient encounters. Inpatient blood culture utilization varied by diagnosis, ranging from 4% for asthma and 46% for SSTI ( Fig 1) . Specifi cally, over the 1-year study period, there were 29 blood cultures in 707 inpatients with asthma, 35 blood cultures in 237 inpatients with bronchiolitis, 139 blood cultures in 381 inpatients with CAP, and 140 blood cultures in 304 inpatients with SSTI. Table 1 describes characteristics of all inpatients according to diagnosis and shows variation between those with and without blood culture collection. For inpatients with asthma and bronchiolitis, LOS was statistically greater in the cohort that had blood cultures drawn compared with the cohort that did not have blood cultures drawn, and a similar trend toward statistical signifi cance was seen in patients with SSTI. No change in LOS was seen in patients with CAP. For patients with CAP, there was a statistically significant difference in median age (2 vs 3 years) in the cohort with blood culture collection compared with the cohort without blood culture collection, respectively.
Inpatient Blood Culture Utilization According to Diagnosis
Blood Culture Results
All blood culture results were negative in patients with asthma and bronchiolitis. In patients with CAP, only 1% had true-positive results and 99% were negative or false-positive. In patients with SSTI, 2% were true-positive, and 98% were negative or false-positive ( Fig 2) . Table 2 details results of these 4 falsepositive blood culture results, as well as the 5 true-positive blood culture results, for which there was no apparent change in antibiotic management or hospital stay, although blood culture testing was repeated in several patients.
Financial Impact
In our institution, the approximate charge for a blood culture is $300, with an additional $100 for identifi cation and $150 for sensitivity reports. As mentioned in the Methods section, we used hospital charges but acknowledge that these charges are higher than the true costs of the laboratory tests. In this cohort, for the 1-year study period, there were ~$8700 in charges for blood cultures among the patients with asthma and $10 500 in charges for blood cultures among the patients with bronchiolitis. Among the patients with CAP, charges for both the 2 true-positive blood culture results and the 134 negative blood culture results totaled ~$41 300; this amount does not include the subsequent charges associated with the 3 false-positive blood culture results. For the patients with SSTI, charges for the 3 true-positive and 136 negative culture results totaled ~$42 450; again, this total does not include the charges and costs associated with the false-positive culture result. Gross microbiology charges in our sample approximated $100 000 over the single 
DISCUSSION
In the present study, blood culture utilization varied according to diagnosis as well as setting; specifi cally, patients admitted with CAP and SSTI had the highest rate of blood culture utilization (36% and 46%, respectively). The rate of blood culture utilization for these common inpatient diagnoses was notable, particularly because blood culture utilization did not seem consistent with existing guidelines or literature, nor did it appear to alter clinical management.
Current guidelines and literature do not support blood culture utilization for inpatients with asthma or bronchiolitis. However, in our study population, 4% and 15% of patients with asthma and bronchiolitis, respectively, had blood cultures obtained as part of their inpatient evaluation and management. We acknowledge that these patients with a primary diagnosis of asthma or bronchiolitis may have also been co-diagnosed with pneumonia, which might have infl uenced the decision to obtain a blood culture. However, given that all of the blood culture results for these patients with asthma and bronchiolitis were negative based on our chart review, this represents an area of potential overutilization.
We found no available guidelines specifi cally targeting evaluation and management of SSTI management in pediatrics; however, there are recent guidelines for the management of MRSA, a common cause of SSTI, across different infection types. 16 Even in the era of increasing MRSA colonization and infection, the literature does not support routine blood culture use for SSTI. Wathen and Halloran 21 conducted a single-center, retrospective chart review and found no clinically signifi cant organisms isolated in blood cultures for patients with cellulitis. Malone et al 22 also conducted a single-center chart review study of >500 patients admitted with SSTI. They found no positive blood culture results in patients with uncomplicated SSTI, whereas 12.5% of patients with complicated SSTI (ie, "surgical or Blood culture utilization for inpatient pneumonia management is controversial. The Infectious Diseases Society of America guidelines recommend that blood cultures be obtained in children who fail to demonstrate improvement after the start of appropriate antibiotic therapy or who require hospitalization for moderate to severe and complicated CAP. 17 However, there are no clear guidelines regarding blood culture utility in mild and uncomplicated CAP, and there is a low reported prevalence of bacteremia in children hospitalized with uncomplicated CAP (range: 1.1%-2.7%). 18, 23 As a result, recent literature questions the need for routine blood cultures in all inpatients with CAP. A recent multicenter, retrospective study found that 56% of hospitalized children with CAP underwent blood culture testing, and there was a 7.1% overall rate of true bacteremia. 24 However, there was less bacteremia in patients with uncomplicated CAP (5.9%) than in those with complicated CAP (10.0%), and in patients who had a pleural drainage (21.2%) than in those with no drainage procedure (5.7%). In another recent single-center study with >300 children, Heine et al 25 determined that 47% of inpatients with pneumonia had blood cultures obtained, and that only 1.5% of all patients had a true-positive blood culture result. However, all 5 positive blood culture results occurred in patients with radiographic effusion or empyema. These authors propose that not all patients admitted for CAP are "moderately to severely ill" and therefore do not warrant routine blood culture testing. Specifi cally, they suggest that well-appearing patients without evidence of effusion or empyema do not need a blood culture collected. Although we did not stratify uncomplicated from complicated CAP, one-third of these patients had a blood culture collected; 99% were negative or false-positive, and the 2 true-positive results yielded no apparent change in clinical management. These fi ndings may demonstrate low utility of blood culture testing in CAP, although there is evidence to support blood culture collection in complicated pneumonia. However, future research is also needed to determine if bacteremia requires a management change.
Overall, these fi ndings suggest blood culture overcollection for most of the diagnoses studied. In our study, 99% of collected blood culture (338 of 343 blood cultures) results were identifi ed as negative or false-positive (contaminants), which suggests overcollection of blood cultures for these common diagnoses at our institution. These outcomes identify opportunities for clinical practice guideline development or refi nement. At a minimum, this represents ~$100 000 in microbiology charges over the single year at our institution. Although these charges overrepresent true hospital cost, it is a useful proxy for the economic burden. In addition, these charges do not account for the impact on the patient and family. However, in the era of value-based health care, every dollar counts; therefore, reducing blood culture utilization is a key component of high-quality care.
Our study has several limitations. First, this was a retrospective study. Data collection was limited by what was coded according to the ICD-9 scheme, and it was not possible to determine whether there were other risk factors (eg, ill appearance, failure of outpatient management) for bacteremia present that prompted blood culture utilization. This study was conducted at a single center, and therefore practice patterns refl ect only those at this center. Also, we did not exclude patients who may have been pretreated with antibiotics at referring facilities, which could have led to a falsely low positive blood culture rate. Finally, we describe only microbiology charges as a marker for fi nancial burden, rather than true costs as described earlier, and do not account for other costs of care, including other laboratory tests, antibiotics, professional services, procedures, and hospital room, as well as family loss of income and emotional impact on the patient and family.
CONCLUSIONS
In the era of value-based health care, every dollar spent must yield highquality care. We identifi ed multiple areas of potential resource overutilization in common inpatient pediatric diagnoses, primarily related to overcollection of blood cultures. These represent opportunities for clinical practice guideline development or refi nement.
In addition, quality improvement efforts can further refi ne collection technique. Finally, clinical research is necessary to determine optimal management of clinically meaningful bacteremia.
